Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
247
-
Total 13F shares, excl. options
-
113M
-
Shares change
-
+7.1M
-
Total reported value, excl. options
-
$4.28B
-
Value change
-
-$265M
-
Put/Call ratio
-
0.36
-
Number of buys
-
159
-
Number of sells
-
-166
-
Price
-
$38.04
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q3 2023
417 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q3 2023.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 247 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113M shares
of 125M outstanding shares and own 89.93% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (15.2M shares), Avoro Capital Advisors LLC (11.1M shares), EcoR1 Capital, LLC (10.9M shares), VANGUARD GROUP INC (9.47M shares), T. Rowe Price Investment Management, Inc. (6.52M shares), BlackRock Inc. (5.27M shares), JENNISON ASSOCIATES LLC (3.54M shares), STATE STREET CORP (3.24M shares), Octagon Capital Advisors LP (3.13M shares), and FMR LLC (2.26M shares).
This table shows the top 247 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.